What kind of targeted drug is Quizartinib?

Quizatinib is a potent, oral, fms-like tyrosine kinase3 (FLT3) inhibitor that occupies a unique position in the field of anticancer drugs. As the first drug developed specifically to target FLT3, quizartinib has shown remarkable results in the treatment of acute myeloid leukemia (AML). Unlike other drugs with FLT3 inhibitory activity, which are often developed with other targets in mind, Quizartinib focuses on FLT3 as a specific target, allowing for more precise treatment.

FLT3is a receptor tyrosine kinase expressed in hematopoietic stem cells and progenitor cells. It plays a key role in the occurrence and development of AML. FLT3 mutations, especially FLT3-ITD (internal tandem duplication) mutations, are one of the most common molecular abnormalities in AML and are closely related to poor prognosis of patients. Quizartinib inhibits the activity of FLT3 kinase and blocks the cell signaling pathway driven by FLT3 mutations, thereby inhibiting the proliferation and survival of leukemia cells.

In clinical practice, quizartinib is mainly used to treat FLT3-ITD mutation-positive AML patients. It is often used as a monotherapy or in combination with other chemotherapy drugs to enhance the effectiveness of the treatment. The recommended dose and administration of quizartinib will be based on the patient's specific condition and tolerance. During the treatment process, doctors will closely monitor the patient's response and possible side effects, such as prolonged QT interval, nausea, vomiting, diarrhea, etc., and adjust the treatment plan as needed.

Quizatinib was developed and marketed asAMLA new hope for patients. As a targeted therapeutic drug targeting FLT3 mutation, it not only improves the survival rate and quality of life of patients, but also promotes the development of precision medicine in the field of leukemia treatment. As more clinical trials are conducted and research deepens, quizartinib is expected to play a greater role in the future and bring good news to more AML patients.

xa0

Reference: https://go.drugbank.com/drugs/DB12874